• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • Diagnostic Delay (in development)
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day Calendar
    • March of Faces
    • Patient Fellows Program
    • Global CRLI
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Diagnostic Delay (in development)

New Training Program Aims to Reduce ALS/MND Diagnostic Delays 

LONDON, EN & EDINBURGH, SC (June 9, 2025) – The International Alliance of ALS/MND Associations has announced a new training program to tackle one of the most urgent challenges for people with ALS/MND: delayed diagnosis. Sponsored by My Name’5 Doddie Foundation, this initiative will equip healthcare professionals with the knowledge and tools to identify ALS/MND symptoms sooner and accelerate referrals to specialists. 

Currently, it can take months to years for people with ALS/MND (Amyotrophic Lateral Sclerosis/Motor Neurone Disease) to receive a correct diagnosis — a delay that limits access to care, treatment, and clinical trials.  The Alliance is developing this new program to improve diagnosis time globally, particularly in those areas without ALS/MND speciality clinics. 

“Every day matters when you’re living with ALS/MND,” said Cathy Cummings, CEO of the International Alliance. “Our program will give healthcare professionals around the world the knowledge and confidence they need to identify ALS/MND symptoms earlier, so patients can get help as early as possible.” 

The training is designed for early-career doctors, secondary care specialists, and other frontline healthcare professionals most likely to encounter ALS/MND in its early stages. The curriculum, led by Orla Hardiman, Professor of Neurology at Trinity College Dublin, will address common problems that delay diagnosis, including: 

  • Missing early warning signs 
  • Misconceptions that “nothing can be done” for patients 
  • Inefficient referral pathways to specialists 

“My Name’5 Doddie Foundation is proud to support this important initiative,” said Nicola Roseman, CEO of My Name’5 Doddie Foundation. “Faster diagnosis means better care, more treatment options, and greater access to research opportunities for people living with MND.” 

The program will be developed in 2025, with pilot presentations at key events such as the Allied Health Professionals Forum in December. The full training will be available globally in 2026. 

About the International Alliance of ALS/MND Associations: The International Alliance of ALS/MND Associations is a global network of ALS/MND organizations working together to improve care, support, and advance research for people affected by ALS/MND worldwide. 

About My Name’5 Doddie Foundation: My Name’5 Doddie Foundation was established in November 2017 by rugby legend Doddie Weir OBE and his fellow trustees. The Foundation aims to fund research into effective treatments for MND and investigate potential cures, and provide grants to help individuals with MND live as fulfilled a life as possible.  

Primary Sidebar

  • Mike Small, Motor Neurone Disease (MND) Association, UK

    Mike Small, Motor Neurone Disease (MND) Association, UK

  • Willi Klein

    Willi Klein

  • Michel Perrozzo, ARSLA, Diagnosed 2015, France

    Michel Perrozzo, ARSLA, Diagnosed 2015, France

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Steven Gallagher, Canada

    Steven Gallagher, Canada

  • Sébastien Batiot, Diagnosed 2012 , ARSLA, France

    Sébastien Batiot, Diagnosed 2012 , ARSLA, France

  • Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

    Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

  • Jose Rivero Muñoz, Diagnosed 2015, FYADENMAC, Mexico

    Jose Rivero Muñoz, Diagnosed 2015, FYADENMAC, Mexico

  • Colm Francis Davis, Ireland

    Colm Francis Davis, Ireland

  • March of Faces Photo Submission_OLGA_ELA ARGENTINA

    March of Faces Photo Submission_OLGA_ELA ARGENTINA

  • Wilfried Leusing, Diagnosed 2010 , DGM, Germany

    Wilfried Leusing, Diagnosed 2010 , DGM, Germany

  • Shay Rishoni

    Shay Rishoni

  • Alfredo Santos, Diagnosed 2013 , ACELA, Colombia

    Alfredo Santos, Diagnosed 2013 , ACELA, Colombia

  • Diana Fernandez, Diagnosed 2009 , Asociación ELA Argentina

    Diana Fernandez, Diagnosed 2009 , Asociación ELA Argentina

  • John and Loretta Russo, USA

    John and Loretta Russo, USA
    final3878

  • 393647_2252248542053_984912751_n

    393647_2252248542053_984912751_n

  • Monica Soriano, Diagnosed 2011 ,  Asociación ELA , Argentina

    Monica Soriano, Diagnosed 2011 , Asociación ELA , Argentina

  • Jorge Melo, ABrELA, Brazil

    Jorge Melo, ABrELA, Brazil

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Brian Lovell, Diagnosed 2011 . MND Australia

    Brian Lovell, Diagnosed 2011 . MND Australia

  • Carlos Alberto Báez Murillo, ACELA, Colombia

    Carlos Alberto Báez Murillo, ACELA, Colombia

  • Steve Gallagher, ALS Society of Canada

    Steve Gallagher, ALS Society of Canada
    Picture1

  • Richard Clark, MND New Zealand,  Diagnosed 2011

    Richard Clark, MND New Zealand, Diagnosed 2011

  • Ian Gale, MND Australia

    Ian Gale, MND Australia

  • Glen Elison,  ALS Hope Foundation,  Diagnosed 2019,  USA

    Glen Elison, ALS Hope Foundation, Diagnosed 2019, USA

  • Claudia Gotti, Brazil

    Claudia Gotti, Brazil

  • Joy Blakeley, Diagnosed 2017 , MND Australia

    Joy Blakeley, Diagnosed 2017 , MND Australia

  • Joyce Rusinak, Forbes Norris ALS Center, USA

    Joyce Rusinak, Forbes Norris ALS Center, USA

  • John Dinon, MND Australia

    John Dinon, MND Australia

  • Ann Nicol

    Ann Nicol

  • Steve

    Steve

  • Phil Rossall, MND-Association, UK

    Phil Rossall, MND-Association, UK

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Wiebke Braach, Deutsche Gesellschaft für Muskelkranke, Germany

    Wiebke Braach, Deutsche Gesellschaft für Muskelkranke, Germany

  • Antonio Ventriglia,  ALS Liga Belgium,  Diagnosed 2013

    Antonio Ventriglia, ALS Liga Belgium, Diagnosed 2013

  • Guoqiang Xu, Diagnosed 2016 , Shaanxi ALS Association, China

    Guoqiang Xu, Diagnosed 2016 , Shaanxi ALS Association, China

  • 83

    83

  • Verónica Isabel Castro Molina, Diagnosed 2014, Argentina

    Verónica Isabel Castro Molina, Diagnosed 2014, Argentina

  • Fabio Carvalho, Associação Pró-Cura da ELA, Brazil

    Fabio Carvalho, Associação Pró-Cura da ELA, Brazil

  • Claudette Sturk, ALS Society of Canada

    Claudette Sturk, ALS Society of Canada
    Picture2

  • Robbie Caliste, UK

    Robbie Caliste, UK

  • Steve Lufkin, USA

    Steve Lufkin, USA
    IMG_3993

  • Dawn Morton, Diagnosed 2014 , MND Scotland, UK

    Dawn Morton, Diagnosed 2014 , MND Scotland, UK

  • Mark Miller

    Mark Miller

  • Liam Dwyer, England

    Liam Dwyer, England

  • IMG_1211

    IMG_1211

  • England-Lee-Millard, UK

    England-Lee-Millard, UK

  • Wilfried Leusing

    Wilfried Leusing

  • Anita Forte, Les Turner ALS Foundation, USA

    Anita Forte, Les Turner ALS Foundation, USA

  • Philip Brindle,  MND Association,  Diagnosed 2015,  England

    Philip Brindle, MND Association, Diagnosed 2015, England

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login